A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

Phase 4 Completed 41 enrolled University of Colorado, Denver Janssen Pharmaceuticals · collab National Center for Research Resources (NCRR) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and Eating Disorder Inventory -2 scores than subjects on placebo. Hypothesis 2: Subjects on risperidone will reach and maintain at or above 90% Ideal body weight sooner than controls.

Timeline

Start: 2004-08
Primary completion: 2009-12
Completion: 2009-12

Publications

Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, O'Lonergan T, Frank G, Wamboldt MZ. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011 Sep;50(9):915-24. doi: 10.1016/j.jaac.2011.06.009. Epub 2011 Aug 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Risperidone	Other / unclassified	4 mg	—

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

Summary

Timeline

Publications

Drugs

Indications